ClinicalTrials.gg
Enrolling by invitationNCT06041581SHADESUpdated Nov 17, 2026

SHADES Mechanistic Trial

An interventional study of Sleep Healthy Using The Internet (SHUTi) and Telephonic CBT-I in Insomnia, Insomnia Chronic and Insomnia, Primary, sponsored by Indiana University. Enrolling by invitation at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Indiana University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 17, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Sleep Initiation and Maintenance Disorders by Indiana University — 4 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Indiana University.

Planned enrollment
2nd of 10
200 · median 29
Started
2024
with 1 other
No phase
10 of 10
4 open now
Registered
8th of 10
by date

Among the 10 studies in Sleep Initiation and Maintenance Disorders by Indiana University, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2024, is one of 10 with no phase, and was the 8th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

4 of the 10 studies in Sleep Initiation and Maintenance Disorders by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sleep Initiation and Maintenance Disorders by Indiana University, or all of them as a file.
02

Study summary

Cardiovascular disease (CVD) is common, deadly, and costly, and adults with insomnia represent a large group of people at elevated risk of developing CVD in the future. This clinical trial will determine if our updated insomnia treatment, called the SHADES intervention, improves CVD factors thought to explain how insomnia promotes CVD and if these improvements are due to positive changes in sleep factors. A total of 200 primary care patients with insomnia and CVD risk factors will be randomized to 6 months of the SHADES intervention (internet, telephonic, and/or face-to-face cognitive-behavioral therapy for insomnia) or the active control condition (sleep education/hygiene, symptom monitoring, and primary care for insomnia). Before and after treatment, participants will complete measurements of the CVD factors (systemic inflammation, autonomic dysfunction, metabolic dysregulation, proinflammatory gene expression) and the sleep factors (insomnia symptoms, sleep onset latency, wake after sleep onset, sleep efficiency). Researchers will test whether the SHADES intervention produces greater improvements in the CVD factors than the active control condition.

Read the detailed description

Cardiovascular disease (CVD) affects nearly 1 in 2 U.S. adults, is the #1 killer of men and women, burdens disadvantaged groups, and has costs greater than any other condition. While these statistics highlight the importance of CVD prevention, current approaches have only partial effectiveness. This has created a need to identify new CVD prevention targets, their underlying mechanisms, and effective interventions. Insomnia, its candidate mechanisms, and insomnia treatment are strong candidates in this regard. Thirty years of evidence indicates that insomnia is an independent, clinically important, robust, and potentially causal and modifiable risk factor for CVD. In addition, biologically plausible mechanisms that could explain how insomnia promotes the development of CVD have been proposed, with the most strongly supported being systemic inflammation, autonomic dysfunction, and metabolic dysregulation. Because insomnia now receives limited attention in settings where CVD prevention occurs (e.g., primary care), there is a large cohort of patients with an unaddressed CVD risk factor (insomnia). This status quo and the strong state of the insomnia-to-CVD science create the current need for a well-powered, mechanistic trial to elucidate biological mechanisms underlying the insomnia-to-CVD relationship and the mechanisms of action of cognitive-behavioral therapy for insomnia (CBT-I), both of which are presently unknown. Therefore, we are conducting a mechanistic trial of 200 primary care patients (45% minority) with insomnia and CVD risk factors but no clinical CVD. Participants will be randomized to 6 months of the SHADES (Strengthening Hearts by Addressing DisruptEd Sleep) intervention or the active control condition. The SHADES intervention is our modernized collaborative care intervention consisting of well-established internet, telephonic, and/or face-to-face CBT-I. The active control condition consists of sleep education/hygiene, symptom monitoring, and primary care for insomnia. Our proposal has four aims - Aim 1: determine the effect of the SHADES intervention on our primary CVD mechanism of high-sensitivity CRP; Aim 2: determine the effect of the SHADES intervention on our secondary CVD mechanisms of systemic inflammation, autonomic dysfunction, and metabolic dysregulation; Aim 3: examine if 6-month improvements in upstream sleep mechanisms mediate the SHADES intervention effect on 6-month improvements in downstream CVD mechanisms; Exploratory Aim: explore the effect of the SHADES intervention on proinflammatory gene expression. This trial could generate the critical support for the mechanistic rationale and conceptual framework needed to justify the next-step phase III, multi-site clinical trial to determine the SHADES Intervention effect on CVD clinical outcomes, endpoints of great public health relevance, morbidity, and cost.

03

Conditions studied

  • Insomnia
  • Insomnia Chronic
  • Insomnia, Primary
  • Sleep Disturbance
  • Sleep Disorder
  • Cardiovascular Diseases
  • Heart Diseases
  • Coronary Artery Disease
  • Stroke
  • Autonomic Dysfunction
  • Systemic Inflammatory Response
  • Metabolic Disease

Keywords

  • Primary Care
  • Internet Interventions
  • Cognitive-Behavioral Therapy for Insomnia
  • Insomnia
  • Cardiovascular Diseases
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Current primary care patient in Eskenazi Health
  2. Age ≥40 years
  3. Clinically elevated insomnia symptoms: During screening, trained trial staff will administer the Insomnia Severity Index (ISI). We will consider patients to have clinically elevated insomnia symptoms if they have an ISI score ≥10 (97% sensitivity and 64% specificity for insomnia disorder).
  4. Elevated CVD risk defined as ≥2 (if 40-59 years) or ≥1 (if 60+ years) of the following risk factors in the Eskenazi Health electronic health record (EHR) in the past 5 years: hypertension, hypercholesterolemia, diabetes, or smoking

Exclusion criteria

Exclusion criteria

  1. History of clinical CVD defined as a self-reported CVD diagnosis during screening or any of the following in the patient's Eskenazi Health EHR before enrollment: myocardial infarction, unstable angina, coronary artery disease, cerebrovascular disease, heart failure, percutaneous coronary intervention, or coronary artery bypass graft
  2. Sleep disorder diagnosis other than insomnia (e.g., sleep apnea, restless legs syndrome, narcolepsy, REM sleep behavior disorder, and non-24-hour sleep-wake disorder)
  3. Ever received treatment for sleep apnea
  4. A schedule requiring a usual bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am (thus preventing adoption of intervention strategies)
  5. Major inflammatory conditions: /AIDS, chronic kidney disease, systemic inflammatory disease (e.g., rheumatoid arthritis, lupus, Crohn's disease, and ulcerative colitis), or active cancer/current cancer treatment
  6. Current pregnancy
  7. Severe cognitive impairment defined as ≥3 errors on a validated 6-item cognitive screen
  8. History of bipolar disorder or psychosis defined as a self-reported diagnosis of bipolar disorder, schizophrenia, or a psychotic disorder during screening or a schizophrenia diagnosis or a bipolar disorder diagnosis in the patient's Eskenazi Health EHR before enrollment
  9. Acute risk of suicide
  10. Inability to read and understand English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    SHADES Intervention

    The SHADES intervention is a 6-month, modernized, collaborative care intervention in which a multidisciplinary team delivers established insomnia treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that harnesses technology to maximize access to and convenience of effective treatments and to minimize personnel, training, and space requirements. Our Intervention Team consists of an insomnia clinical specialist, a clinical behavioral sleep medicine and CBT-I delivery expert, a sleep research/medicine expert, and the patients' primary care providers. Treatments to be delivered are CBT-I in different modalities - internet, phone, and face-to-face - all of which are empirically supported.

    Behavioral: Sleep Healthy Using The Internet (SHUTi) · Behavioral: Telephonic CBT-I · Behavioral: Face-to-Face CBT-I

  • Active comparator
    Active Control

    Active Control (AC) consists of sleep education and hygiene (study staff), symptom monitoring (study staff), and usual primary care for insomnia (clinical staff).

    Other: Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care

Interventions

  • BehavioralSleep Healthy Using The Internet (SHUTi)

    Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.

  • BehavioralTelephonic CBT-I

    Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.

  • BehavioralFace-to-Face CBT-I

    Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.

  • OtherActive Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care

    A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.

06

What researchers measure

Primary outcomes

  1. High-Sensitivity C-Reactive Protein (hsCRP)

    The primary outcome is 6-month change in hsCRP assessed by the Human CRP Quantikine ELISA (R\&D Systems). hsCRP is a circulating inflammation biomarker that is implicated in the pathophysiology of CVD and is a predictor of future CVD events.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Interleukin-6 (IL-6)

    A secondary outcome is 6-month change in IL-6 assessed by the validated MSD MULTI-SPOT® Assay System and 5 plex Proinflammatory Panel 1 Human Kit. IL-6, a proinflammatory cytokine that stimulates production of CRP, is moderately correlated with CRP, and is predictive of future CVD events.

    Time frame: Baseline, 6 months

  2. Pre-Ejection Period (PEP)

    A secondary outcome is 6-month change in resting PEP, an index of sympathetic activation, which will be assessed following established guidelines. Autonomic dysfunction measures are predictors of future CVD events.

    Time frame: Baseline, 6 months

  3. High-Frequency Heart Rate Variability (HF HRV)

    A secondary outcome is 6-month change in resting HF-HRV, an index of parasympathetic activation, which will be assessed following established guidelines. Autonomic dysfunction measures are predictors of future CVD events.

    Time frame: Baseline, 6 months

  4. Hemoglobin A1c (HbA1c)

    A secondary outcome is 6-month change in HbA1c. HbA1c will be measured by an immunoturbidimetric method on a Randox Daytona Clinical Analyzer. HbA1c is the gold standard measure of glycemia. HbA1c is a predictor of CVD events.

    Time frame: Baseline, 6 months

  5. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

    A secondary outcome is 6-month change in HOMA-IR. HOMA-IR will be computed from fasting glucose (glucose oxidase method on a Randox Daytona Clinical Analyzer) and insulin (two antibody immunoassay on a Roche cobas e411 Analyzer). HOMA-IR is an established index of insulin resistance that correlates highly with the invasive euglycemic clamp. HOMA-IR is a predictor of CVD events.

    Time frame: Baseline, 6 months

07

Study locations

1 site
  • Department of Psychology, School of Science, Indiana University Indianapolis
    Indianapolis, Indiana 46202, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 39 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Apr 25, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 5 exclusion criteria edited, 3 added, 2 removed
What changed in the criteria
Inclusion criteria
  • ChangedBefore Current insomnia disorder: During screening, ResNet assistants will administer the Insomnia Severity Index (ISI), a validated screener in primary care. Patients who have ISI scores ≥10 (97% sensitivity, 64% specificity) and remain eligible after ResNet screening will be called by our Insomnia Clinical Specialist, who will administer the Structured Clinical Interview for DSM-5 Sleep Disorders to confirm insomnia disorder.Now Clinically elevated insomnia symptoms: During screening, trained trial staff will administer the Insomnia Severity Index (ISI). We will consider patients to have clinically elevated insomnia symptoms if they have an ISI score ≥10 (97% sensitivity and 64% specificity for insomnia disorder).
  • EditedElevated CVD risk: Elevated CVD risk will be defined as ≥2 (if 40-59 years) or ≥1 (if 60+ years) of the following risk factors in the Eskenazi Health electronic health record (EHR) in the past 5 years: hypertension, hypercholesterolemia, diabetes, or smoking.
Exclusion criteria
  • EditedHistory of clinical CVD: defined as a self-reported CVD diagnosis during screening or any of the following in the patient's electronic health recordEskenazi Health EHR before enrollment: myocardial infarction, unstable angina, coronary artery disease, cerebrovascular disease, heart failure, percutaneous coronary intervention, or coronary artery bypass graft
  • EditedSleep disorder diagnosis other than insomnia (e.g., sleep apnea, restless legs syndrome, narcolepsy, REM sleep behavior disorder, and non-24-hour sleep-wake disorder)
  • RemovedContinuous positive airway pressure (CPAP) use or a STOP-BANG Questionnaire score ≥5, which is indicative of high probability of sleep apnea
  • AddedEver received treatment for sleep apnea
  • EditedA schedule requiring a usual bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am (thus preventing adoption of intervention strategies)
  • EditedMajor inflammatory conditions (: HIV/AIDS, chronic kidney disease, systemic inflammatory disease (e.g., rheumatoid arthritis, lupus, Crohn's disease, and ulcerative colitis), or active cancer)/current cancer treatment
  • EditedSevere cognitive impairment (defined as ≥3 errors on a validated 6-item cognitive screen)
  • RemovedHistory of bipolar disorder or psychosis
  • AddedHistory of bipolar disorder or psychosis defined as a self-reported diagnosis of bipolar disorder, schizophrenia, or a psychotic disorder during screening or a schizophrenia diagnosis or a bipolar disorder diagnosis in the patient's Eskenazi Health EHR before enrollment
  • AddedInability to read and understand English
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Eligibility 2 inclusion criteria edited; 5 exclusion criteria edited, 3 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Current insomnia disorder: During screening, ResNet assistants will administer the Insomnia Severity Index (ISI), a validated screener in primary care. Patients who have ISI scores ≥10 (97% sensitivity, 64% specificity) and remain eligible after ResNet screening will be called by our Insomnia Clinical Specialist, who will administer the Structured Clinical Interview for DSM-5 Sleep Disorders to confirm insomnia disorder.Now Clinically elevated insomnia symptoms: During screening, trained trial staff will administer the Insomnia Severity Index (ISI). We will consider patients to have clinically elevated insomnia symptoms if they have an ISI score ≥10 (97% sensitivity and 64% specificity for insomnia disorder).
    • EditedElevated CVD risk: Elevated CVD risk will be defined as ≥2 (if 40-59 years) or ≥1 (if 60+ years) of the following risk factors in the Eskenazi Health electronic health record (EHR) in the past 5 years: hypertension, hypercholesterolemia, diabetes, or smoking.
    Exclusion criteria
    • EditedHistory of clinical CVD: defined as a self-reported CVD diagnosis during screening or any of the following in the patient's electronic health recordEskenazi Health EHR before enrollment: myocardial infarction, unstable angina, coronary artery disease, cerebrovascular disease, heart failure, percutaneous coronary intervention, or coronary artery bypass graft
    • EditedSleep disorder diagnosis other than insomnia (e.g., sleep apnea, restless legs syndrome, narcolepsy, REM sleep behavior disorder, and non-24-hour sleep-wake disorder)
    • RemovedContinuous positive airway pressure (CPAP) use or a STOP-BANG Questionnaire score ≥5, which is indicative of high probability of sleep apnea
    • AddedEver received treatment for sleep apnea
    • EditedA schedule requiring a usual bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am (thus preventing adoption of intervention strategies)
    • EditedMajor inflammatory conditions (: HIV/AIDS, chronic kidney disease, systemic inflammatory disease (e.g., rheumatoid arthritis, lupus, Crohn's disease, and ulcerative colitis), or active cancer)/current cancer treatment
    • EditedSevere cognitive impairment (defined as ≥3 errors on a validated 6-item cognitive screen)
    • RemovedHistory of bipolar disorder or psychosis
    • AddedHistory of bipolar disorder or psychosis defined as a self-reported diagnosis of bipolar disorder, schizophrenia, or a psychotic disorder during screening or a schizophrenia diagnosis or a bipolar disorder diagnosis in the patient's Eskenazi Health EHR before enrollment
    • AddedInability to read and understand English
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06041581
Lead sponsor
Indiana University
Responsible party
Jesse Stewart (Professor of Psychology, Indiana University) — Principal investigator
First posted
Sep 18, 2023
Start date
Apr 25, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jesse C Stewart, Ph.D.
principal investigator · Indiana University Indianapolis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion